Management ChangeJul 23, 2026, 09:16 AM
Longeveron Appoints Deborah D. Ascheim, M.D., to Board of Directors
AI Summary
Longeveron Inc. announced the election of Deborah D. Ascheim, M.D., to its Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician with over 30 years of experience in advancing gene, cell, and biologics therapies for various diseases. Her appointment is expected to support the company's clinical development of its stem cell therapy, laromestorcel, particularly for its Hypoplastic Left Heart Syndrome (HLHS) program.
Key Highlights
- Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors.
- Dr. Ascheim brings over 30 years of clinical and executive experience in gene, cell, and biologics therapies.
- She has served as Chief Medical Officer for StrideBio, Inc. and Capricor Therapeutics Inc.
- Dr. Ascheim's expertise includes advancing therapies for rare, ultra-rare, and common diseases.
- Longeveron is developing laromestorcel for conditions like HLHS, Alzheimer's, and Pediatric DCM.
Price Impact
More from LGVN